J&J Medical Connect
RYBREVANT®

(amivantamab-vmjw)

J&J Medical Connect

Connect with us

Connect with us

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

RYBREVANT® (amivantamab-vmjw)

Medical Information

RYBREVANT - Storage and Stability of Diluted Solution

Last Updated: 03/03/2026

SUMMARY  

  • The company cannot recommend any practices, procedures, or storage conditions that deviate from the approved product labeling.
  • Diluted solutions should be administered within 10 hours (including infusion time) at room temperature 59°F to 77°F (15°C to 25°C).1
  • Please refer to product labeling for storage and stability information.1

Literature Search

A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File (and/or other resources, including internal/external databases) was conducted on 03 March 2026.

 

References

Show
1 RYBREVANT (amivantamab-vmjw) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; https://jnjlabels.com/package-insert/product-monograph/prescribing-information/RYBREVANT-pi.pdf